Analysts Expect BioVie Inc. (NASDAQ:BIVI) to Post -$0.37 EPS

Brokerages expect BioVie Inc. (NASDAQ:BIVI) to post ($0.37) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for BioVie’s earnings. BioVie reported earnings per share of ($0.22) during the same quarter last year, which would suggest a negative year over year growth rate of 68.2%. The business is expected to announce its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that BioVie will report full-year earnings of ($2.86) per share for the current year. For the next fiscal year, analysts forecast that the firm will post earnings of ($2.36) per share. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of analysts that follow BioVie.

BIVI has been the topic of a number of recent analyst reports. B. Riley cut their price objective on BioVie from $50.00 to $27.00 and set a “buy” rating on the stock in a research note on Tuesday, November 30th. Zacks Investment Research raised BioVie from a “hold” rating to a “buy” rating and set a $5.75 target price on the stock in a report on Monday, December 27th.

Several large investors have recently made changes to their positions in BIVI. Vanguard Group Inc. grew its holdings in shares of BioVie by 267.6% during the 2nd quarter. Vanguard Group Inc. now owns 97,804 shares of the company’s stock worth $1,658,000 after purchasing an additional 71,197 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in shares of BioVie during the 2nd quarter worth approximately $473,000. swisspartners Ltd. grew its holdings in shares of BioVie by 45.0% during the 3rd quarter. swisspartners Ltd. now owns 80,521 shares of the company’s stock worth $542,000 after purchasing an additional 25,000 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of BioVie by 8.0% during the 2nd quarter. Geode Capital Management LLC now owns 22,898 shares of the company’s stock worth $388,000 after purchasing an additional 1,698 shares in the last quarter. 5.96% of the stock is currently owned by institutional investors.

Shares of BIVI stock traded up $0.03 during trading on Friday, reaching $4.47. The company had a trading volume of 13,630 shares, compared to its average volume of 34,188. The firm’s 50 day simple moving average is $5.46 and its two-hundred day simple moving average is $8.68. BioVie has a one year low of $4.35 and a one year high of $46.10.

BioVie Company Profile

BioVie, Inc is a biopharmaceutical company, which discovers, develops and commercializes drug therapies for liver disease. It focuses on BIV201, which treats ascites due to chronic liver cirrhosis. The company was founded on April 10, 2013 and is headquartered in Santa Monica, CA.

Featured Story: What is included in the gross domestic product?

Get a free copy of the Zacks research report on BioVie (BIVI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BioVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioVie and related companies with MarketBeat.com's FREE daily email newsletter.